Fig. 2. Cumulative distribution function for change from baseline in Uterine Fibroid Symptom and Health-Related Quality of Life questionnaire (UFS-QOL) Revised Activities subscale score at end of treatment (end of treatment in VENUS I and end of treatment course 1 in VENUS II): pooled VENUS I and VENUS II. The vertical line denotes the responder threshold. A responder is defined as a patient who achieved 30 or more points of improvement in change from baseline on the Revised Activities subscale score of the UFS-QOL at end of treatment. UPA, ulipristal acetate.

Lukes. Ulipristal for Uterine Leiomyomas: Quality of Life. Obstet Gynecol 2019.